Advice
Following a full submission.
Niaspan is not recommended for use within NHS Scotland for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia.
Limited information comparing Niaspan with standard release nicotinic acid tablets showed similar efficacy in improving lipid parameters and a similar adverse-effect profile. However, there is a lack of information from prospective, double-blind trials comparing Niaspan with statins, fibrates and in combination with other lipid-lowering agents.
Download detailed advice20KB (PDF)
Medicine details
- Medicine name:
- Nicotinic acid modified release tablets (Niaspan®)
- SMC ID:
- 93/04
- Indication:
- Dyslipidaemia
- Pharmaceutical company
- Merck Serono Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 13 April 2004